Advisory Board


Greg Strathe, DVM

Dr. Strathe has been a practicing veterinarian for over 20 years. He is co-owner of one of the largest animal hospitals in Oklahoma. Dr. Strathe’s interests include internal medicine, surgery, dentistry, and overall preventative health of his patients. Dr. Strathe has been involved with Cure Pharmaceutical the past 2 years. He has tested numerous products and compliance with his patients using the strip technology and delivery system. Dr. Strathe Graduated KSU vet school in 1993, Bachelors in Arts & Science KSU 1998.

Michael Neely, MD

Dr. Neely is the director of the University of Southern California Laboratory of Applied Pharmacokinetics, which has been at the forefront of nonparametric population pharmacokinetic modeling techniques and dose optimization for individual patients for over 35 years. He is an Associate Professor of Pediatrics, Clinical Scholar at the University of Southern California (USC) and at Children’s Hospital Los Angeles. His research and clinical interests are in pediatric clinical pharmacometrics, including population pharmacokinetic and pharmacodynamic modeling, pharmacogenomics, simulation, and most importantly, use of models to optimize therapy for individual patients. He has a Master of Science degree in Clinical and Biomedical Investigations from USC, with a focus on applied Bayesian approaches to clinical trial design and pharmacokinetic modeling. He is a member of the United States Food and Drug Administration Anti-­infective Drug Advisory Committee and board certified in pediatrics, pediatric infectious diseases and a Fellow of the American College of Clinical Pharmacology. He completed a four-year NIH career development award, and is the Principle Investigator for two R01 awards from the NIH totaling over 6 million dollars over 5 years to develop and apply pharmacometric techniques to anti-infective therapy in populations and individual patients. Dr. Neely has over 50 publications in peer-reviewed journals, and is invited to give talks and workshops on dose individualization and optimization worldwide.

Ian Sephton

Ian Sephton is currently the CEO of Syncromatics, a SaaS and technology integration company disrupting the mobility market. Prior to that role he Co-Founded Hangar202 an early stage investment firm and The Branstetter Group a retail hospitality ideation firm. With over 20 years of C-level experience in retail and technology markets, Ian currently sits on the board of 5 private companies and Cure Pharmaceutical a publicly traded drug delivery technology company. Ian remains active in social causes tied to veteran rights and homelessness in Downtown Los Angeles. As a former Marine and serial entrepreneur Ian believes a company without a social mission is a ship without a compass. He believes strongly that the technology developed by Cure Pharmaceutical can improve lives and is dedicated to supporting the company with his diverse leadership experience and strategic marketing expertise. Ian earned his undergraduate degree from California Lutheran University and sits on the business school advisory board. He earned his MBA from the University of Southern California.